Organized by
UNITED Scientific Group
A non-profit organization

VACCINES R&D™

**International Conference on Vaccines Research & Development is a federally registered trademark (reg.no. 5226683) owned by USG United Scientific Group

PROGRAM

10th International Conference on

VACCINES RESEARCH & DEVELOPMENT™

November 5-7, 2025

EXHIBITORS

labcorp

药明康德 WuXi AppTec

Four Points by Sheraton
Wakefield Boston Hotel &
Conference Center,
One Audubon Rd, Wakefield, MA

Vaccines R&D-2025 is organized by USG-United Scientific Group, a non-profit scientific organization with tax-exempt status under Section 501(c)(3) of the United States Internal Revenue Code.

VACCINES R&D-2025

November 5-7, 2025

International Conference on Vaccines Research and Development is a part of successful series of conference started from 2015 and held annually since then.

Baltimore, MD 2015

Colombia 2016

Washington, D.C. 2017

Baltimore, MD 2018

Boston, MA 2019

Virtual 2021

Boston, MA 2022

Baltimore, MD 2023

Boston, MA 2024

Vaccines R&D Demographics (2015-2024)



VACCINES R&D-2025

November 5-7, 2025

About

With sincere respect and deep gratitude to the scientists from both academia and industry, doctors, and other professionals for all the efforts in developing the vaccines needed to protect and save lives around the world, we are excited to share with you the first glimpse of the **Tenth Edition- International Conference on Vaccines Research and Development** on **November 5-7, 2025**, at **Boston, MA** (**Vaccines R&D-2025**).

Vaccines R&D-2025 will be a platform for inspiring interdisciplinary exchange at the forefront of rapid and very much needed vaccine research. It includes series of keynote lectures, oral presentations & short-talks, panel discussions involving luminaries in the field, up-coming talent.

The three-day program is filled with rich scientific content covering the novel findings and latest research from the expert speakers from industry, government, and academia; with active participants including top executives from companies, clinicians, academicians, federal researchers, policymakers, and other high-level decision-makers. With this varied kind of participation come plenty of opportunities to seek out funding for new research, commercials of new products and technologies, quality feedback, learnings collaborations, and many new options to explore.

For more information, please visit our website: https://vaccines.unitedscientificgroup.org/

We look forward to welcoming you to Boston for dedicated in-person meeting and networking in November!

Vaccines R&D Topics

- Novel approaches for vaccine development
- COVID vaccines
- Cancer vaccines
- HIV vaccines
- Emerging diseases (Coronavirus, Zika, Dengue, Ebola, Nipah, others)
- Influenza / respiratory vaccines
- Fungal / bacterial / AMR / parasitic / STD vaccines
- Adjuvants
- Vaccine delivery technology
- Immune response
- Clinical trials and development
- Thermo stabilized vaccines
- Vaccine production
- Antigen design
- Veterinary vaccines
- Clinical trials and vaccine responsiveness
- Vaccine process development and manufacturing
- Structure-based vaccine design
- Malaria vaccines
- Bacterial vaccines
- Viral vaccines
- Influenza
- Clinical assays / high-throughput real-time virus neutralization assays
- HPV
- Lipid nanoparticles LNP

Sending Your Team? Group Discounts Available!

If you would like to register a team of 4 or more, please email vaccines@uniscigroup.org for your additional discount coupon code before registering. If you have any questions about registrations, please call us on +1-469-854-2281.

Funding !

Sponsorship for students (only) who are unable to pay with less or no funding, please write to vaccines@uniscigroup.org to get complimentary tickets to the full conference.

labcorp

VACCINE DEVELOPMENT & SOLUTION-BASED DISCOVERY

Comprehensive suite of discovery vaccine testing services, enabling the development of human and veterinary vaccines against viral and bacterial pathogens. With more than four decades of experience working with a variety of vaccine types within a full range of *in vivo* and *in vitro* services, we are the ideal partner for all your vaccine development needs.

***In vitro* capabilities**

- Humoral immune response analysis: Analyze various antibody response types by ELISA, neutralization assays, HAI and other tests in our well-equipped laboratories
- Cell-mediated immune response: Decipher Th1 and Th2 responses by ELISpot in a dedicated tissue culture facility

***In vivo* capabilities**

- Immunogenicity studies: Select from a variety of host species ranging from rodents to NHPs with rapid study starts and scalability from a few to a large number of animals
- Efficacy/challenge: Evaluate your vaccine's efficacy in our vivariums supporting up to BSL2 pathogens in custom-developed or standard research models

Vaccine Discovery | Bio Analytics | Toxicology

NON – GLP

Immunogenicity / Dose Response and Efficacy Studies

Min. Dose Selection

Adjuvant Selection (includes adjuvant safety, testing for potentiating of immune response and injection site reaction)

Lead Optimization Activities - Generates POC

Immuno - Pharmacology (Efficacy Studies/POC)

In vitro | *In vivo*

Immunogencity Studies

Dose Response Studies

Potency Determination

Passive Immunization Studies In Animal Models (in special cases)

Vaccine Specific Humoral and Cellular Immune Response Method Validation

Vaccine Specific Humoral and Cellular Immune Response Method Development

Non-GLP Reactogencity Studies

Visit our website

DAY-01 Wednesday, 05, November 2025

Keynote Presentations

08:30		**Erica Dawson** Chief Research and Development Officer, InDevR	**Innovation in Analytical Characterization Tools for Vaccine Development**
09:05		**Arthur Krieg** Founder and CEO, Zola Therapeutics; Adjunct Professor, UMass Chan Medical School RNA Therapeutics Institute	**Advances in Nucleic Acid Vaccine Adjuvants: *In Vitro* and *In Vivo* Activity of RNA/DNA TLR7/8/9 Agonists for *In Situ* Vaccination of Cancer**
09:40		**Andrew Lees** CEO and Chief Scientific Officer, Fina BioSolutions	**Overview of Conjugate Vaccines and Conjugate Vaccine Development**

Break (10:15-10:45)

10:45		**Stephen L. Hoffman** Chief Executive and Scientific Officer, Sanaria Inc.	**The Path to Licensure of Sanaria® Pf-SPZ-LARC2 Vaccine for Prevention of Plasmodium falciparum (Pf) Malaria in Travelers, Pregnant Women, Children, and Entire Populations for Pf Elimination**
11:20		**Peter Pitts** President and Co-founder of the Center for Medicine in the Public Interest	**Trust Through Transparency**
11:55		**Farshad Guirakhoo** Chief Scientific Officer, ExpreS2ion Biotechnologies ApS	**TBA**

Group Picture (12:30)

Lunch Break (12:40-13:30)

13:30-13:45	**Exhibitor Talk-Labcorp**
13:45-14:00	**Exhibitor Talk-Wuxi AppTec**

Featured Presentations

Cancer & HIV

14:00-14:25 **Ana Jaklenec**, Principal Investigator at the David H. Koch Institute for Integrative Cancer Research at MIT
TBA

14:25-14:50 **Alessio Lanna**, CEO, Sentcell Ltd.; Professor, University College London, UK
Pharmacological Mimicry of Elite-like Humans Eradicates HIV Infection

14:50-15:15 **Shixia Wang**, Chief Scientific Officer, Conigen Bioscience Inc.
Engineered Novel CD4 Cis-dimer Protein Significantly Enhances the Binding of HIV-1 Envelope Glycoproteins and Neutralizing Activities Against HIV-1 Tier 2

15:15-15:40 **Marie-Claire Gauduin**, Professor, Disease Intervention and Prevention, Texas Biomedical Research Institute
Durable HIV Vaccine Targeting Mucosal Epithelium

Break (15:40-16:00)

16:00-16:25 **Michael D. Miller**, Consultant & Author, HealthPolCom
Declining Vaccine Access and R&D Funding

Panel Discussion (16:25-17:10)

Poster & Drinks (17:15-18.15)

VRD-P1 **Lexi Hammer**, Integral Molecular
Virus-like Particles Enable Multiple Readouts to Evaluate Neutralizing Responses to Influenza

VRD-P2 **Shamim Ahmed**, Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota
Low-Dose mRNA-LNP HIV-1 Vaccine Induces Clonal Antibody Expansion and Viral Suppression in Humanized DRAGA Mice

VRD-P3 **Fan Yan**, Acuitas Therapeutics, Canada
Development of mRNA-LNP for Cancer Vaccine

VRD-P4 **Ashley Beavis**, Virology Platform, Sanofi Vaccines
A High Throughput, 384-well Plate Format Neutralization Assay for Influenza

VRD-P5 **Ghania Chikh**, Senior Director, Vaccine Development, Acuitas Therapeutics, Inc.
Novel Lipids with Improved Activity for Prophylactic Vaccine Development

VRD-P6 **Shiferaw Tesfaye Tilahun**, International Vaccine Institute, South Korea
Trends and Patterns of Clinical Trials in East Africa: Analysis of a Decade of Data from the WHO International Clinical Trials Registry Platform

VRD-P7 **Tasawar Iqbal**, Institute of Physiology and Pharmacology, University of Agriculture, Pakistan
Plant-Produced Rabies Vaccines for Veterinary Use in Companion and Wild Animals

VRD-P8 **Igor V. Evsyukov**, ATG Service Gene Company, Russia
Versatile Platform for Designing Safe and Effective Vaccines Across Multiple Pathogens

VRD-P9 **Seyedreza Banihashemi**, Department of R&D, Razi Vaccine Serum Research Institute, Iran
Innovative Strategies in Nasal Vaccination Against Respiratory Infections: Insights from the Razi Cov Pars Vaccine

DAY-02 Thursday, 06, November 2025

Vaccine Development

08:30-08:55 **Christina Go**, Application Scientist, Integral Molecular
Reporter Virus Tools to Expedite Vaccine Development for Rapidly Evolving Viral Pathogens

08:55-09:20 **Kirsten Strahlendorf**, Global Senior Unit Head Vaccine Drug Product Development, Global BioProcess Development, Sanofi, Canada
Vaccine Stability Results in Both X-Ray and Gamma Irradiated Bulk Vessels

09:20-09:45 **Michael P. Citron**, Infectious Disease/Vaccines, Merck & Co., Inc.
Nasal Inoculation ≠ Intranasal Immunization

09:45-10:10 **Courtney L. Finch**, Director of Pre-Clinical, Research & Development, Sabin Vaccine Institute
Nonclinical Efficacy Studies Support Use of Chimpanzee Adenovirus Type 3-Based Marburg and Sudan Virus Vaccines in Outbreak Settings

Break (10:10-10:40)

10:40-11:05 **Ghania Chikh**, Senior Director, Vaccine Development, Acuitas Therapeutics, Inc.
Novel Lipids with Improved Activity for Prophylactic Vaccine Development

11:05-11:30 **Malcolm Begg**, Apollo Therapeutics, UK
APL-10456; An Adjuvanted Rhinovirus Clinical Vaccine Candidate which Generates Cross-species Humoral and Th1-polarized Cellular Immunity

11:30-11:55 **Joshua McGee**, CSO & Co-Founder, Keylicon Biosciences Inc.
Enhancing Self-Amplifying RNA Vaccines: Optimized Chemistry & Sequences for Improved Potency and Therapeutic Window

11:55-12:20 **Edward Robb**, Chief Strategy Officer, Anivive LifeSciences Inc.
Microbiological Safety of a Gene Deleted, Live Attenuated Δcps1 *Coccidioides posadasii* Vaccine: Review of Lack of Revision to Virulence/Shed Spread, Tissue Trophism and Non-target Species Evaluations

12:20-12:45 **Michael Kishko**, Head of Pseudoviral Production Lab - Vaccine, Sanofi
A Computationally Designed Prefusion Stabilized Human Metapneumovirus Fusion Protein Vaccine Antigen Elicited a Potent Neutralization Response

Lunch Break (12:45-13:35)

13:30-13:45 **Exhibitor Talk-3**

Technology & Delivery Platforms

13:50-14:15 **Douglas V. Faller**, Chief Medical Officer, Imunon, Inc.
Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines

14:15-14:40 **Joachim Rader**, Soft Matter Physics and Center for NanoScience, Ludwig-Maximilians-Universität München, Germany
pH-Dependent Mesophase Transitions as Key Determinants of Lipid Nanoparticle Function: Toward Controlled Gene Expression

14:40-15:05 **Frédéric Tangy**, CSO, Oncovita-Institut Pasteur, France
***In Situ* Cancer Vaccination with Modified Measles Virus Induces RIG-I–dependent Tumor Clearance and Immune Memory**

15:05-15.30 **Jia (Zoe) Meng**, WuXi AppTec
Establishment of a Comprehensive Platform for Empowering the Discovery of Viral Vaccines

15:30-15:55 **Eva K. Lee**, Director, Center for Operations Research in Medicine and Healthcare, Morehouse School of Medicine
Advancing Precision Immunization: Predicting Vaccine Immunogenicity through Genomic Integration

Coffee & Networking

DAY-03 Friday, 07, November 2025

Bacteria, Virus, Fungi, and Infectious Diseases

08:55-09:20 **Karen A. Norris**, Professor, Center for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia; CEO, NXT Biologics
Advancing a Broadly Protective Vaccine for the Prevention of Fungal Infections

09:20-09:45 **Cristina E. Martina**, Research Professor, Center for Structural Biology, Vanderbilt University
Designing Broad Next-generation Vaccines Against Alphaviruses

09:45-10:10 **Florian Douam**, Assistant Professor of Microbiology, Boston University Chobanian and Avedisian School of Medicine
A Lentiviral-based Vaccine Platform Against Orthoflaviviruses

10:10-10:35 **Yingjie Lu**, Boston Children's Hospital, Harvard Medical School
Development of a Salmonella and Shigella Eight Valent MAPS vaccine

Immune Characterization and Vaccination

11:05-11:30 **Jason T. George**, Assistant Professor, Department of Biomedical Engineering, Department of Translational Medical Sciences, Texas A&M University
Biophysical Modeling for Accurate T Cell Repertoire-Antigen Specificity Prediction

11:30-11:55 **WooJung Jon**, Associate Professor, Korea Advanced Institute of Science and Technology (KAIST), South Korea
WHO Pathogen Access and Benefit-Sharing for Digital Sequence Information and the Convention on Biological Diversity: Resolving the Intersection of WHO PABS, DSI, and CBD Frameworks

Brenda Nakafeero Simbwa, Uganda National Institute of Public Health, Uganda
Willingness to Receive Ebola Vaccines Among Pregnant and Lactating Women in Kampala, Uganda: Insights from a Post-Outbreak Cross-sectional Study

Isaac D. Olorunshola, Associate Professor and Consultant (Mycoplasmology Specialty). Department of Veterinary Microbiology Faculty of Veterinary Medicine, University of Ilorin, Nigeria
Mycoplasma Bovis: A Review of Vaccination and Diagnostic Initiatives

Lunch Break

Virtual Presentations

Bernd Blobel, University of Regensburg, Medical Faculty, Germany
Managing Healthcare Transformation towards Intelligent and Ethical Personalized, Preventive, Predictive, Participative Precision Medicine Ecosystems

Mariano Votta, Director of Active Citizenship Network, Responsible EU Affairs at Cittadinanzattiva, Italy
Grassroots Mobilisation: Leveraging Civil Society and Community Leadership to Bridge Gaps in Vaccine Coverage

Emmanuel Oladiran Amos, Department of Biochemistry, University of Ilorin, Nigeria
Discovery of Immune-stimulating Epitopes from Glycoproteins E1, E2, and the Capsid Protein in Sindbis Virus for Vaccine Design: An Immunoinformatics Study

Leonardo de Oliveira El-Warrak, Federal University of Rio de Janeiro - UFRJ, Brazil
TWINVAX: Conceptual Model of a Digital Twin for Immunisation Services in Primary Health Care

Yolandy Lemmer, Principal Scientist, Department of Biochemistry, Genetics and Microbiology, University of Pretoria, South Africa
Bridging the Gap: Advancing Recombinant Vaccine Technologies from Innovation to Commercialization

Why Boston?

A global hub of science, innovation, and history, Boston is home to world-renowned institutions like Harvard, MIT, the Broad Institute, Dana-Farber, and Mass General — making it the perfect setting for a cell biology conference.

With 1,000+ biotech and pharma companies, including Moderna, Biogen, and Vertex, Boston seamlessly connects cutting-edge research with real-world impact.

Venue

Four Points by Sheraton Wakefield Boston Hotel & Conference Center
One Audubon Rd, Wakefield, MA 01880
United States.

Phone: 781-876-6008

Hotel Website: https://www.marriott.com/en-us/hotels/bosff-four-points-wakefield-boston-hotel-and-conference-center/overview/

Nearest Airport:
Boston Logan International Airport (BOS)

Distance: Around 12 miles (19.3 km)

Travel Time: About 20-30 minutes by drive

Nearby Attractions



MIT Museum

Boston Common

Freedom Trail

Organized by

UNITED Scientific Group
A non-profit organization

USG United Scientific Group
(A non-profit organization)
8105, Rasor Blvd - Suite #112 PLANO, TX 75024, USA
Ph: +1-469-854-2280/81; **Toll Free:** +1-844-395-4102; **Fax:** +1-469-854-2278
Email: vaccines@uniscigroup.org **Web:** https://vaccines.unitedscientificgroup.org/